GBC develops its first drug, P113, a therapeutic peptide drug for the topical treatment of Oral Candidiasis. P113 finishes its promising Phase IIb FDA clinical trial, proving effective for gingivitis, candida albicans, vaginal Candidiasis, Cystic fibrosis, and anti-plague for dogs’ teeth.